No effect of CYP450 and P‐glycoprotein on hydroxyurea in vitro metabolism
暂无分享,去创建一个
D. Bachir | F. Galactéros | A. Astier | A. Hulin | A. Habibi | Hind Sassi
[1] David C. Smith,et al. Population pharmacokinetics of hydroxyurea in cancer patients , 2009, Cancer Chemotherapy and Pharmacology.
[2] D. Bachir,et al. Plasma and Urine Hydroxyurea Levels Might be Useful in the Management of Adult Sickle Cell Disease , 2007, Hemoglobin.
[3] J. Schellens,et al. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate , 2007, Cancer Chemotherapy and Pharmacology.
[4] G. Camenisch,et al. Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier , 2006, Drug Metabolism and Disposition.
[5] Jinming Huang,et al. Rat liver-mediated metabolism of hydroxyurea to nitric oxide. , 2006, Free Radical Biology & Medicine.
[6] A. di Pietro,et al. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2) , 2006, Anti-cancer drugs.
[7] J. Schellens,et al. Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer , 2006, Clinical pharmacokinetics.
[8] F. Roudot-thoraval,et al. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. , 2006, Haematologica.
[9] Allan H Friedman,et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Asakura,et al. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy , 2005, British journal of haematology.
[11] G. Dresemann. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] S. Thein,et al. The measurement of urinary hydroxyurea in sickle cell anaemia , 2005, British journal of haematology.
[13] K. Ataga,et al. The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease , 2005, Journal of clinical pharmacology.
[14] S. King. Nitric oxide production from hydroxyurea. , 2004, Free radical biology & medicine.
[15] Jinming Huang,et al. Catalase-mediated nitric oxide formation from hydroxyurea. , 2004, Journal of medicinal chemistry.
[16] L. Mangravite,et al. Characterizing the Expression of CYP3A4 and Efflux Transporters (P-gp, MRP1, and MRP2) in CYP3A4-Transfected Caco-2 Cells After Induction with Sodium Butyrate and the Phorbol Ester 12-O-Tetradecanoylphorbol-13-Acetate , 2001, Pharmaceutical Research.
[17] S. Swindells,et al. Pharmacokinetics of Hydroxyurea in Plasma and Cerebrospinal Fluid of HIV‐1‐Infected Patients , 2003, Journal of clinical pharmacology.
[18] E. Vichinsky,et al. Hydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease , 2003, Journal of pediatric hematology/oncology.
[19] S. Ballas,et al. Urease enhances the formation of iron nitrosyl hemoglobin in the presence of hydroxyurea. , 2003, Biochimica et biophysica acta.
[20] O. Castro,et al. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea , 2002, British journal of haematology.
[21] Valentine J. Burroughs,et al. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. , 2002, Journal of the National Medical Association.
[22] Jinming Huang,et al. Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea. , 2002, Journal of the American Chemical Society.
[23] M. Gladwin,et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease , 2002, British journal of haematology.
[24] L. Benet,et al. The drug efflux-metabolism alliance: biochemical aspects. , 2001, Advanced drug delivery reviews.
[25] H. Fasold,et al. Hydroxyurea‐induced oxidative damage of normal and sickle cell hemoglobins in vitro: Amelioration by radical scavengers , 2001, Journal of clinical laboratory analysis.
[26] P. Okunieff,et al. Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes. , 2001, Blood cells, molecules & diseases.
[27] J. Lisziewicz,et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.
[29] A. D. Rodrigues,et al. Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[30] P. Gwilt,et al. Pharmacokinetics and Pharmacodynamics of Hydroxyurea , 1998, Clinical pharmacokinetics.
[31] P. Gwilt,et al. Colorimetric determination of hydroxyurea in human serum using high-performance liquid chromatography. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[32] G. Weiss,et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. , 1998, Blood.
[33] H. Maeda,et al. In vivo production of nitric oxide in rats after administration of hydroxyurea. , 1997, Molecular pharmacology.
[34] D. Schrenk,et al. Expression of the multidrug resistance genes in the liver , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] F. Lori,et al. Pharmacokinetics of Hydroxyurea in Patients Infected with Human Immunodeficiency Virus Type I , 1996, Journal of clinical pharmacology.
[36] M L Terrin,et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.
[37] P. Gwilt,et al. Nonlinear disposition of hydroxyurea. , 1994, Journal of pharmaceutical sciences.
[38] R. Boucher,et al. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. , 1992, The Journal of biological chemistry.
[39] M. Vacca,et al. Hydroxyurea: relationship between toxicity and centrally-induced adrenal activation. , 1990, Pharmacology & toxicology.
[40] M. Goldberg,et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. , 1990, The New England journal of medicine.
[41] A. Schechter,et al. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. , 1990, The New England journal of medicine.
[42] J. Wright,et al. Evidence that the antitumor agent hydroxyurea enters mammalian cells by a diffusion mechanism. , 1986, Biochemical and biophysical research communications.
[43] U. Andrae. Evidence for the involvement of cytochrome P-450-dependent monooxygenase(s) in the formation of genotoxic metabolites from N-hydroxyurea. , 1984, Biochemical and biophysical research communications.
[44] R. Belt,et al. Studies of hydroxyurea administered by continuous infusion. Toxicity, pharmacokinetics, and cell synchronization , 1980, Cancer.
[45] M. Colvin,et al. The enzymatic reduction of hydroxyurea to urea by mouse liver. , 1970, Cancer research.
[46] R. Adamson,et al. The distribution, excretion and metabolism of hydroxyurea-C14. , 1965, The Journal of pharmacology and experimental therapeutics.